


Clinical Need



NORMAL VALVE

DEGENERATIVE MR –
PROLAPSE

DEGENERATIVE MR –
FLAIL

FUNCTIONAL MR


~2-10%¹
of the US
population
has mitral
regurgitation
(MR)

2M+²
of the US
population
has primary or
secondary MR

~17%³
all-cause
mortality rate
for moderate
to severe MR

No solution exists for moderate or severe MR patients who are ineligible for Mitraclip or surgery


Market Opportunity




Estimated Carpentier type II mitral regurgitation (13,600 patients) and mitral valve stenosis (3400 patients) for SOM

Current Solutions


Percutaneous repair



Surgical repair




MV Replacement



Percutaneous MV replacement tends to create left ventricular outflow tract (LVOT) obstruction

Our Solution

- Access percutaneously
- Cut and retrieve diseased leaflets
- Available for low and high risk patients
- Reduce open heart surgeries
- Mitigate LVOT obstruction



Project Timeline

Concept Generation

IP / Market
Assessment

Prototype
Development

Business Plan
Formulation

Contact Us

MTM Team: Mitsuhiro Jo: mjozee@berkeley.edu | Janani Balaji: jananibalaji16@berkeley.edu | Xin Ting Wu: xintingcindywu@berkeley.edu | Francisco Valadez Rojas: francisco_valadez@berkeley.edu

Sponsors: Dr. Elaine Tseng: elaine.tseng@ucsf.edu | Dr. Liang Ge: liang.ge@gmail.com | Brenna Lord: brennahlord@gmail.com